AMENDMENT NO. 1 TO CONFIDENTIALITY AGREEMENTConfidentiality Agreement • February 2nd, 2012 • Amgen Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO CONFIDENTIALITY AGREEMENT (the “Amendment”) is being entered into as of January 6th, 2011 (the “Amendment Effective Date”), between AMGEN INC., a Delaware corporation (together with its Affiliates, “Amgen”), and MICROMET INC., a Delaware corporation (together with its Affiliates, “Micromet”, and each of Micromet and Amgen individually or jointly referred to as “Party” and “Parties”) to amend the Confidentiality Agreement, dated as of August 11, 2011 between the Parties (the “Original Confidentiality Agreement”). Capitalized terms used but not defined herein shall have the respective meanings ascribed thereto in the Original Confidentiality Agreement.
Re: Special Retention AwardAward Agreement • February 2nd, 2012 • Amgen Inc • Biological products, (no disgnostic substances)
This letter agreement (this “Award Agreement”) is to inform you that Amgen Inc. (the “Parent”) is offering you a cash retention award in the amount of One Million Dollars and No Cents ($1,000,000.00), subject to the terms and conditions set forth below (the “Award”). Reference is made to the agreement and plan of merger made and entered into as of January 25, 2012, by and among the Parent, Armstrong Acquisition Corp., a wholly owned subsidiary of the Parent (“Purchaser”), and Micromet, Inc. (“Micromet”), pursuant to which Purchaser will be merged with and into Micromet, with Micromet as the surviving corporation and a subsidiary of the Parent (the “Merger”).
CONFIDENTIALITY AGREEMENTConfidentiality Agreement • February 2nd, 2012 • Amgen Inc • Biological products, (no disgnostic substances) • Delaware
THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of August 11, 2011 (the “Effective Date”), between AMGEN INC., a Delaware corporation (together with its Affiliates (as defined in section 14), “Amgen”), and MICROMET, INC., a Delaware corporation (together with its Affiliates, “Micromet”, and each of Micromet and Amgen individually or jointly referred to as “Party” and “Parties”)
